StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

Research analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Monday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Down 3.1 %

Shares of NASDAQ TXMD opened at $1.26 on Monday. TherapeuticsMD has a 12-month low of $1.15 and a 12-month high of $2.75. The firm’s 50-day moving average is $1.48 and its two-hundred day moving average is $1.69.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP lifted its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the period. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. Institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.